{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:08:03Z","timestamp":1794265683399,"version":"4.9.0"},"reference-count":130,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T00:00:00Z","timestamp":1644796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>The COVID-19 pandemic has resulted in a complex clinical challenge, caused by a novel coronavirus, partially similar to previously known coronaviruses but with a different pattern of contagiousness, complications, and mortality. Since its global spread, several therapeutic agents have been developed to address the heterogeneous disease treatment, in terms of severity, hospital or outpatient management, and pre-existing clinical conditions. To better understand the rationale of new or old repurposed medications, the structure and host\u2013virus interaction molecular bases are presented. The recommended agents by EDSA guidelines comprise of corticosteroids, JAK-targeting monoclonal antibodies, IL-6 inhibitors, and antivirals, some of them showing narrow indications due to the lack of large population trials and statistical power. The aim of this review is to present FDA-approved or authorized for emergency use antivirals, namely remdesivir, molnupinavir, and the combination nirmatrelvir-ritonavir and their impact on the cardiovascular system. We reviewed the literature for metanalyses, randomized clinical trials, and case reports and found positive associations between remdesivir and ritonavir administration at therapeutic doses and changes in cardiac conduction, relatable to their previously known pro-arrhythmogenic effects and important ritonavir interactions with cardioactive medications including antiplatelets, anti-arrhythmic agents, and lipid-lowering drugs, possibly interfering with pre-existing therapeutic regimens. Nonetheless, safety profiles of antivirals are largely questioned and addressed by health agencies, in consideration of COVID-19 cardiac and pro-thrombotic complications generally experienced by predisposed subjects. Our advice is to continuously adhere to the strict indications of FDA documents, monitor the possible side effects of antivirals, and increase physicians\u2019 awareness on the co-administration of antivirals and cardiovascular-relevant medications. This review dissects the global and local tendency to structure patient-based treatment plans, for a glance towards practical application of precision medicine.<\/jats:p>","DOI":"10.3390\/biomedicines10020437","type":"journal-article","created":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T20:26:42Z","timestamp":1644870402000},"page":"437","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Molecular Insights of SARS-CoV-2 Antivirals Administration: A Balance between Safety Profiles and Impact on Cardiovascular Phenotypes"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9705-5360","authenticated-orcid":false,"given":"Francesco","family":"Nappi","sequence":"first","affiliation":[{"name":"Department of Cardiac Surgery, Centre Cardiologique du Nord de Saint-Denis, 93200 Saint-Denis, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3208-4689","authenticated-orcid":false,"given":"Adelaide","family":"Iervolino","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University Policlinic Federico II, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeet Singh","family":"Avtaar Singh","sequence":"additional","affiliation":[{"name":"Department of Cardiothoracic Surgery, Aberdeen Royal Infirmary, Aberdeen AB25 2ZN, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,14]]},"reference":[{"key":"ref_1","unstructured":"(2021, December 31). World Health Organization. Available online: https:\/\/covid19.who.int."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","article-title":"Characteristics of SARS-CoV-2 and COVID-19","volume":"19","author":"Hu","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.bj.2020.10.008","article-title":"SARS-CoV-2, the other face to SARS-CoV and MERS-CoV: Future predictions","volume":"44","author":"Abdelghany","year":"2020","journal-title":"Biomed. J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against COVID-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1021\/acscentsci.0c00489","article-title":"Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19","volume":"6","author":"Eastman","year":"2020","journal-title":"ACS Cent. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e57309","DOI":"10.7554\/eLife.57309","article-title":"SARS-CoV-2 (COVID-19) by the numbers","volume":"9","author":"Flamholz","year":"2020","journal-title":"eLife"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/jama.2020.27124","article-title":"Genetic Variants of SARS-CoV-2\u2014What Do They Mean?","volume":"325","author":"Lauring","year":"2021","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41392-021-00623-2","article-title":"SARS-CoV-2 mutations, vaccines, and immunity: Implication of variants of concern","volume":"6","author":"Noh","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"eabd3876","DOI":"10.1126\/scitranslmed.abd3876","article-title":"Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19","volume":"12","author":"Zuo","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.thromres.2020.04.013","article-title":"Incidence of thrombotic complications in critically ill ICU patients with COVID-19","volume":"191","author":"Klok","year":"2020","journal-title":"Thromb. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jmii.2020.03.022","article-title":"Genotype and phenotype of COVID-19: Their roles in pathogenesis","volume":"54","author":"Mousavizadeh","year":"2020","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"104502","DOI":"10.1016\/j.meegid.2020.104502","article-title":"From SARS to SARS-CoV-2, insights on structure, pathogenicity and immunity aspects of pandemic human coronaviruses","volume":"85","author":"Kirtipal","year":"2020","journal-title":"Infect. Genet. Evol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/jmv.25681","article-title":"Emerging coronaviruses: Genome structure, replication, and pathogenesis","volume":"92","author":"Chen","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/22221751.2020.1725399","article-title":"RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak","volume":"9","author":"Chen","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.chom.2020.02.001","article-title":"Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China","volume":"27","author":"Wu","year":"2020","journal-title":"Cell Host Microbe"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A Novel Coronavirus from Patients with Pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"166725","DOI":"10.1016\/j.jmb.2020.11.024","article-title":"Structural insights into SARS-CoV-2 proteins","volume":"433","author":"Arya","year":"2020","journal-title":"J. Mol. Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/JCMA.0000000000000335","article-title":"Genomic analysis and comparative multiple sequences of SARS-CoV2","volume":"83","author":"Chang","year":"2020","journal-title":"J. Chin. Med. Assoc."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e00127-20","DOI":"10.1128\/JVI.00127-20","article-title":"Receptor Recognition by the Novel Coronavirus fromWuhan: An Analysis Based on Decade-Long Structural Studies of SARS Coronavirus","volume":"94","author":"Wan","year":"2020","journal-title":"J. Virol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41591-020-0820-9","article-title":"The proximal origin of SARS-CoV-2","volume":"26","author":"Andersen","year":"2020","journal-title":"Nat. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1038\/s41564-020-0770-5","article-title":"A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology","volume":"5","author":"Rambaut","year":"2020","journal-title":"Nat. Microbiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/nrmicro2147","article-title":"Coronaviruses post-SARS: Update on replication and pathogenesis","volume":"7","author":"Perlman","year":"2009","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"11727","DOI":"10.1073\/pnas.2003138117","article-title":"Cell entry mechanisms of SARS-CoV-2","volume":"117","author":"Shang","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5553","DOI":"10.1038\/s41467-021-25796-w","article-title":"Characterising proteolysis during SARS-CoV-2 infection identifies viral cleavage sites and cellular targets with therapeutic potential","volume":"12","author":"Meyer","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_29","first-page":"210","article-title":"Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity","volume":"575","author":"Shin","year":"2020","journal-title":"Nature"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41467-020-20718-8","article-title":"The complex structure of GRL0617 and SARS-CoV-2 PLpro reveals a hot spot for antiviral drug discovery","volume":"12","author":"Fu","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"12359","DOI":"10.1021\/acs.jmedchem.0c00606","article-title":"COVID-19: Drug Targets and Potential Treatments","volume":"63","author":"Gil","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Bhimraj, A., Morgan, R.L., Shumaker, A.H., Lavergne, V., Baden, L., Cheng, V.C., Edwards, K.M., Gandhi, R., Gallagher, J., and Muller, W.J. (2020). Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Infectious Diseases Society of America 2022. Clin. Infect. Dis., ciaa478.","DOI":"10.1093\/cid\/ciaa478"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1743-422X-2-69","article-title":"Chloroquine is a potent inhibitor of SARS coronavirus infection and spread","volume":"2","author":"Vincent","year":"2005","journal-title":"Virol. J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41421-020-0156-0","article-title":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro","volume":"6","author":"Liu","year":"2020","journal-title":"Cell Discov."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"(2020). The RECOVERY Collaborative Group Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19. N. Engl. J. Med., 383, 2030\u20132040.","DOI":"10.1056\/NEJMoa2022926"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"WHO Solidarity Trial Consortium, Pan, H., Peto, R., Henao-Restrepo, A.-M., Preziosi, M.-P., Sathiyamoorthy, V., Abdool Karim, Q., Alejandria, M.M., Hern\u00e1ndez Garc\u00eda, C., and Kieny, M.-P. (2021). 1 Repurposed Antiviral Drugs for COVID-19\u2014Interim WHO Solidarity Trial Results. N. Engl. J. Med., 384, 497\u2013511.","DOI":"10.1056\/NEJMoa2023184"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"6737","DOI":"10.1002\/jmv.27259","article-title":"Effect of azithromycin and hydroxychloroquine in patients hospitalized with COVID-19: Network meta-analysis of randomized controlled trials","volume":"93","author":"Chi","year":"2021","journal-title":"J. Med. Virol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e20210236","DOI":"10.36416\/1806-3756\/e20210236","article-title":"Use of hydroxychloroquine to prevent SARS-CoV-2 infection and treat mild COVID-19: A systematic review and meta-analysis","volume":"47","author":"Tanni","year":"2021","journal-title":"J. Bras. Pneumol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e14448","DOI":"10.1111\/ijcp.14448","article-title":"Does hydroxychloroquine reduce mortality in patients with COVID-19? A meta-analysis with trial sequential analysis","volume":"75","author":"Chen","year":"2021","journal-title":"Int. J. Clin. Pract."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"102135","DOI":"10.1016\/j.tmaid.2021.102135","article-title":"Efficacy of chloroquine and hydroxychloroquine in treating COVID-19 infection: A meta-review of systematic reviews and an updated meta-analysis","volume":"43","author":"Chivese","year":"2021","journal-title":"Travel Med. Infect. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"11974","DOI":"10.1038\/s41598-021-91089-3","article-title":"Hydroxychloroquine plus standard of care compared with standard of care alone in COVID-19: A meta-analysis of randomized controlled trials","volume":"11","author":"Amani","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_43","unstructured":"Gordon, A.C. (2021). Interleukin-6 Receptor Antagonists in Critically Ill Patients with COVID-19\u2014Preliminary report. medRxiv."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa2028700","article-title":"Tocilizumab in Hospitalized Patients with Severe COVID-19 Pneumonia","volume":"384","author":"Rosas","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1001\/jamainternmed.2020.6820","article-title":"Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial","volume":"181","author":"Hermine","year":"2020","journal-title":"JAMA Intern. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2030340","article-title":"Tocilizumab in Patients Hospitalized with COVID-19 Pneumonia","volume":"384","author":"Salama","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1001\/jamainternmed.2020.6615","article-title":"Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial","volume":"181","author":"Salvarani","year":"2020","journal-title":"JAMA Intern. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1056\/NEJMoa2028836","article-title":"Efficacy of Tocilizumab in Patients Hospitalized with COVID-19","volume":"383","author":"Stone","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"n84","DOI":"10.1136\/bmj.n84","article-title":"Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: Randomised controlled trial","volume":"372","author":"Veiga","year":"2021","journal-title":"BMJ"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"RECOVERY Collaborative Group (2021). Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): Preliminary results of a randomised, controlled, open-label, platform trial. Lancet, 397, 1637\u20131645.","DOI":"10.1101\/2021.02.11.21249258"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Gatti, M., Turrini, E., Raschi, E., Sestili, P., and Fimognari, C. (2021). Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues. Pharmaceuticals, 14.","DOI":"10.3390\/ph14080738"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/MCC.0000000000000869","article-title":"Janus Kinase inhibitors for the treatment of hospitalized patients with COVID-19","volume":"27","author":"Florescu","year":"2021","journal-title":"Curr. Opin. Crit. Care"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.1007\/s10067-021-05911-4","article-title":"Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: Case presentation and literature review","volume":"40","author":"Mori","year":"2021","journal-title":"Clin. Rheumatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1182\/blood.2020006000","article-title":"COVID-19 and its implications for thrombosis and anticoagulation","volume":"135","author":"Connors","year":"2020","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/ajh.25982","article-title":"Thrombosis in COVID-19","volume":"95","author":"Hanff","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/CRD.0000000000000347","article-title":"Thrombotic Complications of COVID-19 Infection","volume":"29","author":"Castro","year":"2020","journal-title":"Cardiol. Rev."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s11739-020-02621-8","article-title":"Arterial and venous thrombosis in coronavirus 2019 disease (COVID-19): Relationship with mortality","volume":"16","author":"Violi","year":"2021","journal-title":"Intern. Emerg. Med."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Nappi, F., Iervolino, A., and Singh, S.A. (2021). COVID-19 Pathogenesis: From Molecular Pathway to Vaccine Administration. Biomedicines, 9.","DOI":"10.20944\/preprints202106.0135.v1"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1016\/S2213-2600(20)30530-0","article-title":"Corticosteroids for COVID-19: The search for an optimum duration of therapy","volume":"9","author":"Mishra","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"ref_60","first-page":"131729","article-title":"Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: The REMAP-CAP COVID-19 corticosteroid domain randomised clinical trial","volume":"324","author":"Angus","year":"2020","journal-title":"JAMA"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00508-020-01805-8","article-title":"GLUCOCOVID: A controlled trial of methylprednisolone in adults hospitalised with COVID-19 pneumonia","volume":"133","author":"Corral","year":"2021","journal-title":"Wien. Klin. Wochenschr."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1001\/jama.2020.16761","article-title":"Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: A randomised clinical trial","volume":"324","author":"Dequin","year":"2020","journal-title":"JAMA"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2002808","DOI":"10.1183\/13993003.02808-2020","article-title":"Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: Results from a randomised controlled clinical trial","volume":"56","author":"Edalatifard","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalised patients with COVID-19","volume":"384","author":"Horby","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"173947","DOI":"10.1016\/j.ejphar.2021.173947","article-title":"No clinical benefit of high dose corticosteroid administration in patients with COVID-19: A preliminary report of a randomised clinical trial","volume":"897","author":"Jamaati","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.eng.2020.03.007","article-title":"Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study","volume":"6","author":"Cai","year":"2020","journal-title":"Engineering"},{"key":"ref_67","first-page":"166","article-title":"Favipiravir and COVID-19: A Simplified Summary","volume":"71","author":"Pashapour","year":"2020","journal-title":"Drug Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1093\/jac\/dkaa171","article-title":"Favipiravir, an antiviral for COVID-19?","volume":"75","author":"Coomes","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"100719","DOI":"10.1016\/j.drup.2020.100719","article-title":"FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy","volume":"53","author":"Rosik","year":"2020","journal-title":"Drug Resist. Update"},{"key":"ref_70","first-page":"CD014963","article-title":"Systemic corticosteroids for the treatment of COVID-19","volume":"8","author":"Wagner","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A Trial of Lopinavir\u2013Ritonavir in Adults Hospitalized with Severe COVID-19","volume":"382","author":"Cao","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(20)32013-4","article-title":"Lopinavir\u2013ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial","volume":"396","author":"Horby","year":"2020","journal-title":"Lancet"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1186\/s13063-020-04478-w","article-title":"Efficacy of chloroquine versus lopinavir\/ritonavir in mild\/general COVID-19 infection: A prospective, open-label, multicenter, randomized controlled clinical study","volume":"21","author":"Liu","year":"2020","journal-title":"Trials"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s00134-021-06448-5","article-title":"Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial","volume":"47","author":"Arabi","year":"2021","journal-title":"Intensive Care Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"6557","DOI":"10.1002\/jmv.27195","article-title":"Comparing the effectiveness of Atazanavir\/Ritonavir\/Dolutegravir\/Hydroxychloroquine and Lopinavir\/Ritonavir\/Hydroxychloroquine treatment regimens in COVID-19 patients","volume":"93","author":"Kalantari","year":"2021","journal-title":"J. Med. Virol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e216468","DOI":"10.1001\/jamanetworkopen.2021.6468","article-title":"Effect of Early Treatment with Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19: The TOGETHER Randomized Clinical Trial","volume":"4","author":"Reis","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1056\/NEJMp2032369","article-title":"FDA Approval of Remdesivir\u2014A Step in the Right Direction","volume":"383","author":"Rubin","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1021\/acs.jmedchem.6b01594","article-title":"Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses","volume":"60","author":"Siegel","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41467-020-20542-0","article-title":"Mechanism of SARS-CoV-2 polymerase stalling by remdesivir","volume":"12","author":"Kokic","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cell.2020.05.034","article-title":"Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase","volume":"182","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"4773","DOI":"10.1074\/jbc.AC120.013056","article-title":"The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus","volume":"295","author":"Gordon","year":"2020","journal-title":"J. Biol. Chem."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Tchesnokov, E.P., Feng, J.Y., Porter, D.P., and G\u00f6tte, M. (2019). Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir. Viruses, 11.","DOI":"10.3390\/v11040326"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"9372","DOI":"10.1073\/pnas.1201130109","article-title":"RNA 3\u2032-end mismatch excision by the severe acute respiratory syndrome coronavirus nonstructural protein nsp10\/nsp14 exoribonuclease complex","volume":"109","author":"Bouvet","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.molcel.2020.07.027","article-title":"Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting","volume":"79","author":"Robson","year":"2020","journal-title":"Mol. Cell"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"eaal3653","DOI":"10.1126\/scitranslmed.aal3653","article-title":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses","volume":"9","author":"Sheahan","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"JC17","DOI":"10.7326\/ACPJ202102160-017","article-title":"In inpatients with COVID-19, none of remdesivir, hydroxychloroquine, lopinavir, or interferon \u03b2-1a differed from standard care for in-hospital mortality","volume":"174","author":"Zhang","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the Treatment of COVID-19\u2014preliminary report","volume":"383","author":"Beigel","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e02428-20","DOI":"10.1128\/AAC.02428-20","article-title":"Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity against SARS-CoV-2","volume":"65","author":"Painter","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41594-021-00657-8","article-title":"Molnupiravir: Coding for catastrophe","volume":"28","author":"Malone","year":"2021","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e935952","DOI":"10.12659\/MSM.935952","article-title":"Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Patients","volume":"28","author":"Parums","year":"2022","journal-title":"Med. Sci. Monit."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"12997","DOI":"10.1073\/pnas.1601327113","article-title":"SARS-CoV 3CL protease cleaves its C-terminal autoprocessing site by novel subsite cooperativity","volume":"113","author":"Muramatsu","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1002\/med.21783","article-title":"What coronavirus 3C-like protease tells us: From structure, substrate selectivity, to inhibitor design","volume":"41","author":"Xiong","year":"2021","journal-title":"Med. Res. Rev."},{"key":"ref_95","first-page":"1","article-title":"Potential Cardiotoxic Effects of Remdesivir on Cardiovascular System: A Literature Review","volume":"13","author":"Nabati","year":"2021","journal-title":"Cardiovasc. Toxicol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s40264-020-00952-1","article-title":"Remdesivir in Treatment of COVID-19: A Systematic Benefit\u2013Risk Assessment","volume":"43","author":"Davies","year":"2020","journal-title":"Drug Saf."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1023\/A:1009810025584","article-title":"Case report: Adenosine induced ventricular fibrillation in a patient with stable ventricular tachycardia","volume":"5","author":"Parham","year":"2001","journal-title":"J. Interv. Card. Electrophysiol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13256-016-1177-z","article-title":"Adenosine induced ventricular fibrillation in a structurally normal heart: A case report","volume":"11","author":"Rajkumar","year":"2017","journal-title":"J. Med. Case Rep."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/jpids\/piab029","article-title":"Sinus Bradycardia in a Pediatric Patient Treated with Remdesivir for Acute Coronavirus Disease 2019: A Case Report and a Review of the Literature","volume":"10","author":"Chow","year":"2021","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"104955","DOI":"10.1016\/j.antiviral.2020.104955","article-title":"Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes","volume":"184","author":"Choi","year":"2020","journal-title":"Antivir. Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1186\/s13063-020-04352-9","article-title":"Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: Study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial","volume":"21","author":"Wang","year":"2020","journal-title":"Trials."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Jung, S.Y., Kim, M.S., Li, H., Lee, K.H., Koyanagi, A., Solmi, M., Kronbichler, A., Dragioti, E., Tizaoui, K., and Cargnin, S. (2021). Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database. Clin. Transl. Sci.","DOI":"10.1111\/cts.13168"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1161\/CIRCULATIONAHA.114.012869","article-title":"Cardiovascular health and protection against CVD: More than the sum of the parts?","volume":"130","year":"2014","journal-title":"Circulation"},{"key":"ref_105","unstructured":"Food and Drug Administration (2022, February 09). FDA Drug Safety Communication: Ongoing Safety Review of Invirase (Saquinavir) and Possible Association with Abnormal Heart Rhythms, Available online: https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/fda-drug-safety-communication-ongoing-safety-review-invirase-saquinavir-and-possible-association."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"e008798","DOI":"10.1161\/CIRCEP.120.008798","article-title":"Lopinavir-Ritonavir Treatment for COVID-19 Infection in Intensive Care Unit","volume":"13","author":"Beyls","year":"2020","journal-title":"Circ. Arrhythmia Electrophysiol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"euab116.115","DOI":"10.1093\/europace\/euab116.115","article-title":"Cardiac arrhythmias in COVID-19: Mechanisms, outcomes and the potential role of proarrhythmia","volume":"23","author":"Merino","year":"2021","journal-title":"Europace"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/cts.12882","article-title":"Risk Assessment of Drug-Induced Long QT Syndrome for Some COVID-19 Repurposed Drugs","volume":"14","author":"Michaud","year":"2020","journal-title":"Clin. Transl. Sci."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s10557-020-07070-1","article-title":"Lopinavir-Ritonavir in SARS-CoV-2 Infection and Drug-Drug Interactions with Cardioactive Medications","volume":"35","author":"Agarwal","year":"2020","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1111\/bcp.13583","article-title":"Recurrent coronary disease in HIV-infected patients: Role of drug-drug interactions","volume":"84","author":"Bravo","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1742-7843.2012.00932.x","article-title":"Pharmacokinetic Interaction Between Prasugrel and Ritonavir in Healthy Volunteers","volume":"112","author":"Ancrenaz","year":"2012","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/j.metabol.2011.03.015","article-title":"Ritonavir inhibits the two main prasugrel bioactivation pathways in vitro: A potential drug\u2013drug interaction in HIV patients","volume":"60","author":"Daali","year":"2011","journal-title":"Metabolism"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/00002030-200203080-00008","article-title":"Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047","volume":"16","author":"Fichtenbaum","year":"2002","journal-title":"AIDS"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/bcp.12075","article-title":"Co-administration of rivaroxaban with drugs that share its elimination pathways: Pharmacokinetic effects in healthy subjects","volume":"76","author":"Mueck","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/01.qai.0000219774.20174.64","article-title":"Lopinavir\/Ritonavir Induces the Hepatic Activity of Cytochrome P450 Enzymes CYP2C9, CYP2C19, and CYP1A2 But Inhibits the Hepatic and Intestinal Activity of CYP3A as Measured by a Phenotyping Drug Cocktail in Healthy Volunteers","volume":"42","author":"Yeh","year":"2006","journal-title":"JAIDS J. Acquir. Immune Defic. Syndr."},{"key":"ref_116","unstructured":"NORVIR (Ritonavir) (2022, February 09). Summary of Product Characteristics. 26 August 1996 (revised 17 January 2013). Abbott Laoratories Limited, Abbott House, Maidenhead, Berkshire. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/norvir-epar-product-information_en.pdf."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"108042","DOI":"10.1016\/j.jmgm.2021.108042","article-title":"Characterization of the non-covalent interaction between the PF-07321332 inhibitor and the SARS-CoV-2 main protease","volume":"110","author":"Macchiagodena","year":"2021","journal-title":"J. Mol. Graph. Model."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Lange, N.W., Salerno, D.M., Jennings, D.L., Choe, J., Hedvat, J., Kovac, D., Scheffert, J., Shertel, T., Ratner, L.E., and Brown, R.S. (2022). Nirmatrelvir\/ritonavir use: Managing clinically significant drug-drug interactions with transplant immunosuppressants. Am J. Transplant.","DOI":"10.1111\/ajt.16955"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1093\/cvr\/cvaa106","article-title":"COVID-19 and the cardiovascular system: Implications for risk assessment, diagnosis, and treatment options","volume":"116","author":"Guzik","year":"2020","journal-title":"Cardiovasc. Res."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Gemmati, D., Bramanti, B., Serino, M.L., Secchiero, P., Zauli, G., and Tisato, V. (2020). COVID-19 and Individual Genetic Susceptibility\/Receptivity: Role of ACE1\/ACE2 Genes, Immunity, Inflammation and Coagulation. Might the Double X-chromosome in Females Be Protective against SARS-CoV-2 Compared to the Single X-Chromosome in Males?. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21103474"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3389\/fcvm.2020.00071","article-title":"COVID and the Renin-Angiotensin System: Are Hypertension or Its Treatments Deleterious?","volume":"7","author":"Zores","year":"2020","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1002\/ejhf.1871","article-title":"COVID-19 and heart failure: From infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease","volume":"22","author":"Tomasoni","year":"2020","journal-title":"Eur. J. Heart Fail"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.jacc.2016.11.064","article-title":"Roles of Angiotensin Peptides and Recombinant Human ACE2 in Heart Failure","volume":"69","author":"Basu","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"e009458","DOI":"10.1161\/CIRCEP.120.009458","article-title":"Worldwide Survey of COVID-19\u2013Associated Arrhythmias","volume":"14","author":"Coromilas","year":"2021","journal-title":"Circ. Arrhythmia Electrophysiol."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"COVIDSurg Collaborative, and GlobalSurg Collaborative (2022). SARS-CoV-2 infection and venous thromboembolism after surgery: An international prospective cohort study. Anaesthesia, 77, 28\u201339.","DOI":"10.1111\/anae.15563"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"(2021). COVIDSurg Collaborative; GlobalSurg Collaborative Effects of pre-operative isolation on postoperative pulmonary complications after elective surgery: An international prospective cohort study. Anaesthesia, 76, 1454\u20131464.","DOI":"10.1111\/anae.15560"},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Nappi, F., Iervolino, A., and Avtaar Singh, S.S. (2021). Thromboembolic Complications of SARS-CoV-2 and Metabolic Derangements: Suggestions from Clinical Practice Evidence to Causative Agents. Metabolites, 11.","DOI":"10.3390\/metabo11060341"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.athoracsur.2021.02.066","article-title":"Incertitude Pathophysiology and Management During the First Phase of the COVID-19 Pandemic","volume":"113","author":"Nappi","year":"2021","journal-title":"Ann. Thorac. Surg."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"COVIDSurg Collaborative, and GlobalSurg Collaborative (2021). Timing of surgery following SARS-CoV-2 infection: An international prospective cohort study. Anaesthesia, 76, 748\u2013758.","DOI":"10.1111\/anae.15458"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"COVIDSurg Collaborative (2021). GlobalSurg Collaborative SARS-CoV-2 vaccination modelling for safe surgery to save lives: Data from an international prospective cohort study. Br. J. Surg., 108, 1056\u20131063.","DOI":"10.1093\/bjs\/znab101"}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/2\/437\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:19:03Z","timestamp":1760134743000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/2\/437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,14]]},"references-count":130,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["biomedicines10020437"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines10020437","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,14]]}}}